ClinicalTrials.gg
RecruitingNCT05870813CLEAR-BUpdated May 23, 2023

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

An observational study in Breast Cancer, HER2-negative Breast Cancer and Hormone Receptor Positive Breast Carcinoma, sponsored by Institut fuer Frauengesundheit. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Institut fuer Frauengesundheit · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.

Started
2023
the only one that year
Observational
2 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is the only one that started in 2023, is one of 2 observational ones, and was the 7th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, or all of them as a file.
02

Study summary

This is a non-interventional retrospective cohort study of premenopausal patients with HR+/HER2- breast cancer who are treated in the adjuvant setting with either Tamoxifen, Tamoxifen + Ovarial Function Suppression or Aromatase inhibitor + Ovarial Function Suppression.

Read the detailed description

The treatment landscape concerning the adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor positive (HRpos) breast cancer is quite heterogeneous and therapy recommendations can vary. Tamoxifen (TAM) is a common treatment option that does not require OFS, but research suggests that adding OFS to tamoxifen may improve outcomes. Aromatase inhibitors (AI) are another option, but they can only be used with OFS for premenopausal patients. Studies have shown that AI + OFS improves disease-free survival compared to TAM + OFS, but it may lead to additional side effects such as osteopenia and bone fractures.

The CLEAR-B study aims to provide a detailed description of the therapy landscape in this therapeutic setting, including recurrence rates and overall survival with AI compared to TAM, as well as a comparison of the chosen therapies within prognostic subgroups.

CLEAR-B is a retrospective cohort study, collecting data of premenopausal patients who were diagnosed with early-stage breast cancer between January 2016 and June 2019 in a certified breast cancer center. These patients had an intermediate or high risk of cancer recurrence, as defined by (neo)adjuvant chemotherapy, and/or pT≥2cm at the timepoint of definitive surgery and/or at least one positive lymph node at the time of definite surgery (pN+).

The primary objective is to compare the invasive disease-free survival (iDFS) of patients who were treated with AI + OFS vs. those who were treated with TAM ± OFS. Additionally, the study will compare distant disease-free survival (DDFS) and overall survival (OS) between the two groups and perform subgroup analyses according to risk stratification (stage II and III). This study will be conducted at around 75 certified breast cancer centers and will enroll up to 3000 patients.

03

Conditions studied

  • Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Premenopausal patients with early-stage breast cancer who have been diagnosed from January 2016 to June 2019 with an intermediate or high recurrence risk in a certified breast cancer center (DKG/DGS).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with a first primary diagnosis of hormone receptor-positive, - negative unilateral early breast cancer for whom an endocrine treatment is indicated
  • Patients must be at least 18 years of age but not older than 60
  • Premenopausal defined as all statements must be true

    • No oophorectomy before the diagnosis of breast cancer
    • Women with uterus: Regular, physiological menses at the timepoint of therapy decision for anti-endocrine treatment in the absence of and hormonal treatment
    • Women without uterus and remaining ovaries: premenopausal hormone levels must be documented at the time of therapy decision for anti-endocrine treatment
  • Patients with an intermediate or high-risk early-stage breast cancer defined as: At least one of the following must be fulfilled

    • (Neo) chemotherapy
    • pT≥2cm at the timepoint of definitive surgery
    • at least one positive lymph node at the time of definite surgery (pN+)
  • Patient must be previously registered in and must have been documented as part of the certification process for a certified breast cancer center according to the Deutsche Krebsgesellschaft/Deutsche Gesellschaft für Senologie
  • Breast Cancer must have been diagnosed between Jan 2016 and Jun 2019

Exclusion criteria

Exclusion Criteria:

  • Patients with a low recurrence risk (see inclusion criteria for definition)
  • Locally advanced breast cancer or distant at diagnosis
  • Male biological sex
  • Patients not treated in a certified breast cancer center
  • Treatment with CDK4/6Previous diagnosis of invasive breast cancer or in situ breast cancer
  • Concurrent invasive
  • Bilateral breast cancer at the timepoint of diagnosis
  • Previous diagnosis of invasive breast cancer or in situ breast cancer is not allowed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • AI+OFS

    adjuvant treatment with aromatase inhibitor + OFS (ovarian function suppression)

  • TAM

    Patients started the adjuvant treatment with Tamoxifen ± OFS

06

What researchers measure

Primary outcomes

  1. iDFS

    The primary study aim is to show that aromatase inhibitor (AI) based treatments (AI arm) are not inferior to treatments based on tamoxifen (tamoxifen arm) in terms of invasive diseasefree survival (iDFS). iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  2. Comparison of iDFS

    In case non-inferiority is confirmed, the superiority of Cohort AI+OFS over Cohort TAM will be tested with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

Secondary outcomes

  1. Comparison of DDFS

    To analyze the non-inferiority of the Cohort AI+OFS compared with the Cohort TAM with regard to distant disease-free survival (DDFS). DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  2. Comparison of OS

    To analyze the non-inferiority of the Cohort AI+OFS compared with the Cohort TAM with regard to overall survival (OS). In case non-inferiority is confirmed, the superiority of Cohort AI+OFS over Cohort TAM will be tested with regard to OS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.

    Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years

  3. Comparison of iDFS in Cohort TAM

    To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  4. Comparison of DDFS in Cohort TAM

    To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  5. Comparison of OS in Cohort TAM

    To compare patients within the Cohort TAM who were treated with OFS and those who were not treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.

    Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years

  6. Comparison of iDFS (TAM+OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were treated with OFS with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  7. Comparison of DDFS (TAM+OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were treated with OFS with regard to DDFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  8. Comparison of OS (TAM+OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM who were treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.

    Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years

  9. Comparison of iDFS (TAM-OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were not treated with OFS with regard to iDFS. iDFS will be assessed as time to event. Events for iDFS include: Invasive Ipsilateral Breast Tumor Recurrence (IBTR), Local/Regional Invasive Recurrence, Distant Recurrence, Death from BC, Death from Non-BC Cause, Death From unknown cause, Invasive Contralateral BC, Second Primary Invasive Cancer (non-breast)

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  10. Comparison of DDFS (TAM-OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM, who were not treated with OFS with regard to DDFS. DDFS will be assessed as time to event. Events for DDFS include distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause.

    Time frame: First start of adjuvant endocrine therapy until date of the above mentioned events up to 5 years

  11. Comparison of OS (TAM-OFS and AI+OFS)

    To compare patients of Cohort AI+OFS with patients in Cohort TAM who were not treated with OFS. OS is defined as time from first start of adjuvant endocrine therapy until date of death due to any cause.

    Time frame: First start of adjuvant endocrine therapy until date of death up to 5 years

  12. Influence of disease stage

    To conduct multivariate analyses to estimate the influence of disease stage on prognosis.

    Time frame: Baseline until onset of disease progression or death up to 5 years

  13. Risk Factors

    To conduct subgroup analyses for the survival outcomes (iDFS, DDFS, OS) according to risk stratification (stage II and stage III)

    Time frame: Baseline until onset of disease progression or death up to 5 years

  14. NATALEE Comparison

    To compare patients who are matching the inclusion and exclusion criteria of the pivotal study NATALEE and who were treated in Cohort AI+OFS with patients matching the NATALEE population and who were treated in Cohort TAM.

    Time frame: Baseline until onset of disease progression or death up to 5 years

Other outcomes

  1. Therapy frequencies

    To assess the frequency of the different therapies according to risk groups

    Time frame: Baseline

  2. Adherence

    Number of patients with specified reason for therapy termination (recurrence, side effects, patients' wishes etc.)

    Time frame: End of Treatment/ Treatment termination up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2023, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
May 23, 2023
StartActual
Mar 10, 2023
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05870813
Lead sponsor
Institut fuer Frauengesundheit
Collaborators
AGO Breast Study Group e.V., Novartis Pharmaceuticals
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Mar 10, 2023
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
May 23, 2023

Study contacts

CLEAR Study Manager
Contact
clear@ifg-erlangen.de
+49 9131 91 88 0613

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion